A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
about
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionLight Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis †.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Systemic amyloidosis: novel therapies and role of biomarkers.Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac responseNews in AL Amyloidosis ASH 2016: A rapidly evolving field of investigation.Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.Outcomes of patients with renal monoclonal immunoglobulin deposition disease.Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.Dysproteinemias and Glomerular Disease.New concepts in the treatment and diagnosis of amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Prognosis and risk assessment in AL amyloidosis - There and back again.Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.Amyloid in bone marrow smears in systemic light-chain amyloidosis.Light Chain Amyloidosis.
P2860
Q33795363-4B75A459-66B8-406C-AB41-222DB941F7E4Q36254199-33DDB23E-7FA9-4B9E-BE85-C9068F21856EQ36779759-8028D056-20FA-494B-9BD3-D18388985BAAQ37494829-E4B9F2B9-8897-47DE-B3EA-022176A19856Q37570615-F08E32B3-2064-456A-99AF-D815AE3956CFQ38376616-97069AD5-5BDD-4C13-ABCB-6789586935BCQ38600436-162F8DD5-178B-47C1-999D-9FF3B6B4E1F9Q38613822-95BD5EE8-0CA1-48E4-84B4-D0571A330970Q38614967-8992D1DB-49D9-4562-8320-0F0B94983524Q38652107-5324E181-1BF5-4AED-A893-FB6365BB53C2Q38688055-066DB88C-44EE-4718-8FAC-DF8B11ADFEBCQ38829923-0F62B6AF-2365-4293-AD49-0B6CDDE7B2C2Q38831139-A1A83A7D-9DDB-4CA9-923A-A3F612584D91Q38911216-4A31E46B-2622-4D9C-8097-3EC0B5A92CDCQ39217713-2F521FC5-064C-4F60-8F15-7EFC09A52A94Q39272596-0510D76D-5872-4879-BBAC-83D4D6ACB163Q39446111-98605BA5-9F9E-40FB-B061-035B3355D23EQ39820550-277F2AF9-D7C4-4021-8D37-52CE1A67DB26Q40252288-EB2E063F-F61F-40F2-9563-E9D960982939Q40261261-36083906-BF60-4B84-82E0-19DF54121C55Q40274316-2E3A94F1-648B-4937-8253-46F54714BF6FQ40533557-762E8F18-EA8B-4B25-B6F1-C6438FFE887DQ40705462-80E1509A-D934-40B1-A84D-43B83A72E4BEQ40742235-22460CB0-50EC-4702-8CE1-E4FD167A5752Q40918755-63783619-E53E-4E8F-B166-3CD07488B072Q40973226-429292C0-2400-4813-8395-4AD3212F2B94Q41080053-5D56C011-FD49-4CAB-B215-28818A1E7546Q42360535-6C1B0BE4-1D9B-477F-8CFA-759E9685214AQ42392559-88D76D73-7F1A-4397-ABA4-D976AE6C61E7Q46048669-26804DD3-D9EE-4D70-AE53-F7AA97057AE5Q46463218-498A416A-CBFF-4B18-9305-05167478AC73Q47428714-809E1792-8A41-4391-9B1E-8685594C15FDQ47561519-ACCA1D0D-42EF-48F6-B9DA-1BEE69FA31F9Q48156924-DE4ED194-2E12-4BFE-BA8A-67F5A187DBF7Q48239985-E5853FB8-68B6-4B28-AF94-0F69B9FCF17BQ48334990-ABC33FDA-B922-4E9F-A327-4D1F5F426B22Q48614453-314A4DD2-0997-4163-8B66-297718F2AD24Q50071663-A542FC29-5FD4-4ADD-A150-6BA64BFA1B6CQ50209795-613187B3-84A3-4B5A-8067-8A2B80D4771EQ52659305-62519105-79CA-4AD7-94A3-09D8A7BD0ACD
P2860
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
description
article
@en
im August 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2014
@uk
name
A staging system for renal out ...... chemotherapy in AL amyloidosis
@en
A staging system for renal out ...... chemotherapy in AL amyloidosis
@nl
type
label
A staging system for renal out ...... chemotherapy in AL amyloidosis
@en
A staging system for renal out ...... chemotherapy in AL amyloidosis
@nl
prefLabel
A staging system for renal out ...... chemotherapy in AL amyloidosis
@en
A staging system for renal out ...... chemotherapy in AL amyloidosis
@nl
P2093
P50
P1433
P1476
A staging system for renal out ...... chemotherapy in AL amyloidosis
@en
P2093
Andrea Foli
Anthony D Ho
Christoph Kimmich
Marta Vidus Rosin
Remigio Moratti
Riccardo Albertini
Ute Hegenbart
P304
P356
10.1182/BLOOD-2014-04-570010
P407
P577
2014-08-12T00:00:00Z